The ethanolic extract of ashitaba stem (Angelica keskei [Miq.] Koidz) as future antituberculosis
Sri Agung Fitri Kusuma
Mutiara Ayu Dewanti
- Publisher: Wolters Kluwer Medknow Publications
Journal of Advanced Pharmaceutical Technology & Research,
(issn: 2231-4040, eissn: 0976-2094)
Original Article | RM1-950 | Angelica keiskei | Mycobacterium tuberculosis H37Rv | Therapeutics. Pharmacology | tuberculosis | Indonesia | Pharmacy and materia medica | minimum inhibitory concentration | RS1-441
Considering the easy contagion of tuberculosis (TB) disease spread and the emergence of multidrug-resistant TB, which directly impacts the failure of therapeutic goals and mortality rates increasing, TB disease control remains to be the main concern of continuous health development effort. Therefore, the discovery of new TB drug is needed. This research assessed the new natural anti-TB drug from the ethanolic extract of Angelica keiskei stem obtained from Lombok, Indonesia. The objectives of this study were to evaluate the sensitivity of Mycobacterium tuberculosis (Mtb) H37Rv strain to A. keiskei stem extract and to determine its minimum inhibitory concentration (MIC). The extraction methods of A. keiskei stem were done using a maceration method. In addition to phytochemical screening and water content analysis using standard method, the phytochemical parameters were analyzed by thin-layer chromatography. Ethanolic extract of A. keiskei stem was assayed for their Mtb inhibitory activity using the proportion method. The phytochemical analysis result showed that the secondary metabolites contain in the extract were flavonoid, polyphenol, tannin, monoterpenoid and sesquiterpen, quinon, and saponin. The anti-TB test result showed the active activity of ethanolic extract of A. keiskei against Mtb H37Rv strain with MIC ranging from 6% to 8% w/v. In conclusion, ethanolic extract of A. keiskei is a prospective natural anti-TB for the future.